

Table SI. Clinical scores (CESD < 16 vs, CESD ≥ 16) of patients under dupilumab therapy within the TREATgermany registry at start visit dupilumab, after 3 months, 6 months and 12 months

cohort size	CESD < 16				CESD ≥16				Total			
	start dupilumab	3 months	6 months	12 months	start dupilumab	3 months	6 months	12 months	start dupilumab	3 months	6 months	12 months
	n= 316	n= 198	n= 179	n= 151	n= 309	n= 189	n= 165	n= 116	n= 633	n= 392	n= 346	n= 268
IGA												
clear [0]	0 [0.0%]	8 [4.1%]	18 [10.1%]	15 [9.9%]	0 [0.0%]	7 [3.7%]	14 [8.5%]	5 [4.3%]	0 [0.0%]	15 [3.9%]	32 [9.2%]	20 [7.5%]
almost clear [1]	4 [1.3%]	54 [27.6%]	54 [30.2%]	54 [35.8%]	2 [0.6%]	43 [22.9%]	46 [27.9%]	33 [28.7%]	6 [1.0%]	97 [24.9%]	101 [29.2%]	87 [32.6%]
mild [2]	18 [5.7%]	86 [43.9%]	76 [42.5%]	52 [34.4%]	18 [5.8%]	74 [39.4%]	61 [37.0%]	62 [53.9%]	37 [5.9%]	163 [41.9%]	137 [39.6%]	115 [43.1%]
moderate [3]	143 [45.4%]	39 [19.9%]	30 [16.8%]	28 [18.5%]	122 [39.6%]	53 [28.2%]	38 [23.0%]	14 [12.2%]	266 [42.2%]	93 [23.9%]	68 [19.7%]	42 [15.7%]
severe [4]	117 [37.1%]	8 [4.1%]	1 [0.6%]	2 [1.3%]	134 [43.5%]	10 [5.3%]	6 [3.6%]	1 [0.9%]	255 [40.4%]	19 [4.9%]	8 [2.3%]	3 [1.1%]
very severe [5]	33 [10.5%]	1 [0.5%]	0 [0.0%]	0 [0.0%]	32 [10.4%]	1 [0.5%]	0 [0.0%]	0 [0.0%]	67 [10.6%]	2 [0.5%]	0 [0.0%]	0 [0.0%]
oSCORAD [mean]	44.1 ± 14.5	22.8 ± 11.5	19.8 ± 11.0	18.8 ± 9.4	46.7 ± 14.2	24.8 ± 13.6	20.3 ± 11.8	19.8 ± 10.0	45.4 ± 14.3	24.0 ± 12.6	20.1 ± 11.4	19.3 ± 9.7
EASI [mean]	19.6 ± 13.1	5.7 ± 6.2	3.9 ± 4.3	3.5 ± 4.3	20.6 ± 12.9	6.8 ± 8.2	4.3 ± 5.1	4.1 ± 4.4	20.1 ± 13.0	6.4 ± 7.5	4.1 ± 4.8	3.8 ± 4.3
EASI [head]	2.1 ± 1.6	0.8 ± 0.9	0.6 ± 0.7	0.5 ± 0.6	2.1 ± 1.5	0.9 ± 1.1	0.7 ± 0.9	0.7 ± 0.7	2.1 ± 1.6	0.8 ± 1.0	0.6 ± 0.8	0.6 ± 0.7
EASI [body]	5.6 ± 4.4	1.4 ± 2.1	1.1 ± 1.7	1.1 ± 1.6	5.8 ± 4.2	1.7 ± 2.6	1.1 ± 1.7	1.0 ± 1.6	5.7 ± 4.3	1.6 ± 2.4	1.1 ± 1.7	1.0 ± 1.6
EASI [arms]	4.5 ± 3.1	1.4 ± 1.6	0.9 ± 0.9	0.8 ± 1.1	4.8 ± 3.1	1.6 ± 1.9	1.1 ± 1.3	1.2 ± 1.3	4.7 ± 3.1	1.5 ± 1.8	1.0 ± 1.1	1.0 ± 1.2
EASI [legs]	7.5 ± 6.2	2.1 ± 2.8	1.3 ± 1.9	1.1 ± 1.8	7.8 ± 6.3	2.7 ± 4.0	1.5 ± 2.4	1.3 ± 1.9	7.7 ± 6.3	2.4 ± 3.6	1.4 ± 2.3	1.2 ± 1.9
PGA												
clear	0 [0.0%]	13 [6.6%]	12 [6.7%]	11 [7.5%]	0 [0.0%]	7 [3.8%]	8 [5.0%]	7 [6.2%]	0 [0.0%]	21 [5.5%]	20 [5.9%]	18 [6.9%]
almost clear	10 [3.2%]	66 [33.7%]	59 [33.1%]	53 [36.1%]	6 [1.9%]	47 [25.4%]	55 [34.2%]	31 [27.4%]	16 [2.6%]	113 [29.5%]	116 [34.0%]	84 [32.2%]
mild	56 [17.7%]	79 [40.3%]	86 [48.3%]	62 [42.2%]	25 [8.1%]	70 [37.8%]	57 [35.4%]	50 [44.2%]	81 [13.0%]	149 [38.9%]	143 [41.9%]	112 [42.9%]
moderate	99 [31.3%]	33 [16.8%]	19 [10.7%]	19 [12.9%]	84 [27.3%]	39 [21.1%]	30 [18.6%]	18 [15.9%]	183 [29.3%]	72 [18.8%]	49 [14.4%]	37 [14.2%]
severe	118 [37.3%]	5 [2.6%]	2 [1.1%]	2 [1.4%]	122 [39.6%]	19 [10.3%]	10 [6.2%]	6 [5.3%]	240 [38.5%]	25 [6.5%]	12 [3.5%]	9 [3.4%]
very severe	33 [10.4%]	0 [0.0%]	0 [0.0%]	0 [0.0%]	71 [23.1%]	3 [1.6%]	1 [0.6%]	1 [0.9%]	104 [16.7%]	3 [0.8%]	1 [0.3%]	1 [0.4%]
DLQI [mean]	10.1 ± 5.7	3.2 ± 3.7	2.9 ± 3.4	3.3 ± 3.7	17.5 ± 6.8	6.6 ± 6.7	5.8 ± 6.1	5.0 ± 4.9	13.8 ± 7.3	4.9 ± 5.6	4.3 ± 5.1	4.0 ± 4.4
POEM [mean]	17.3 ± 6.2	7.2 ± 5.5	6.6 ± 5.0	6.5 ± 5.2	21.4 ± 5.6	9.8 ± 6.9	8.5 ± 6.1	8.3 ± 5.7	19.4 ± 6.2	8.4 ± 6.3	7.5 ± 5.6	7.3 ± 5.5
Fatigue												
Fatigue [mean]	3.1 ± 1.3	2.6 ± 1.2	2.5 ± 1.2	2.5 ± 1.2	4.7 ± 1.4	3.7 ± 1.6	3.7 ± 1.6	3.5 ± 1.6	3.9 ± 1.6	3.2 ± 1.5	3.0 ± 1.5	2.9 ± 1.5
FSS ≤ 4	239 [75.9%]	173 [88.3%]	154 [86.5%]	130 [87.8%]	104 [33.7%]	111 [60.0%]	95 [59.4%]	74 [65.5%]	343 [55.0%]	286 [74.7%]	251 [73.8%]	205 [78.2%]
FSS > 4	76 [24.1%]	23 [11.7%]	24 [13.5%]	18 [12.1%]	205 [66.3%]	74 [40.0%]	65 [40.6%]	39 [34.5%]	281 [45.1%]	97 [25.3%]	89 [26.2%]	57 [21.8%]
CESD												
CESD [mean]	9.2 ± 4.0	7.7 ± 6.0	8.1 ± 6.1	7.8 ± 6.8	25.7 ± 7.8	17.4 ± 10.0	16.4 ± 10.5	15.0 ± 10.5	17.3 ± 10.3	12.3 ± 9.5	11.9 ± 9.4	10.9 ± 9.3
CESD [0-16]	316 [100.0%]	177 [90.3%]	161 [90.4%]	131 [89.7%]	0 [0.0%]	95 [51.6%]	84 [52.8%]	68 [60.7%]	316 [50.6%]	274 [71.7%]	247 [72.9%]	200 [77.2%]
CESD [16-22]	0 [0.0%]	19 [9.9%]	17 [9.5%]	15 [10.3%]	309 [100.0%]	89 [48.4%]	75 [47.2%]	44 [39.3%]	309 [49.4%]	108 [28.3%]	92 [28.1%]	59 [22.8%]
pain [3 days]	3.8 ± 2.5	1.2 ± 1.6	1.3 ± 1.5	1.2 ± 1.6	5.3 ± 2.6	2.0 ± 2.3	2.1 ± 2.4	2.0 ± 2.3	4.6 ± 2.7	1.6 ± 2.0	1.6 ± 2.0	1.6 ± 1.9
itching [3 days]	6.2 ± 2.3	2.7 ± 2.1	2.5 ± 1.9	2.4 ± 1.9	7.3 ± 2.1	3.5 ± 2.4	3.4 ± 2.6	3.4 ± 2.4	6.8 ± 2.3	3.1 ± 2.3	2.9 ± 2.3	2.9 ± 2.2
insomnia [3 days]	4.6 ± 3.1	1.1 ± 1.8	1.0 ± 1.7	1.1 ± 1.8	6.8 ± 2.9	2.4 ± 2.9	2.3 ± 2.9	2.1 ± 2.7	5.7 ± 3.2	1.7 ± 2.4	1.6 ± 2.4	1.5 ± 2.3
EASI50		146 [74.1%]	153 [86.4%]	134 [89.3%]		151 [81.2%]	141 [87.0%]	102 [89.5%]		300 [77.3%]	296 [86.8%]	237 [89.4%]
EASI75		96 [48.7%]	120 [67.8%]	107 [71.3%]		86 [46.2%]	105 [64.8%]	79 [69.3%]		185 [47.7%]	226 [66.3%]	186 [70.2%]
EASI90		47 [23.9%]	56 [31.6%]	63 [42.0%]		39 [21.0%]	60 [37.0%]	41 [36.0%]		86 [22.2%]	116 [34.0%]	104 [39.2%]

Table SII. Clinical scores (FSS ≤ 4 vs, FSS > 4) of patients under dupilumab therapy within the TREATgermany registry at start visit dupilumab, after 3 months, 6 months and 12 months

cohort size	FSS ≤ 4				FSS > 4				Total			
	start dupilumab	3 months	6 months	12 months	start dupilumab	3 months	6 months	12 months	start dupilumab	3 months	6 months	12 months
	n= 343	n= 221	n= 192	n= 149	n= 281	n= 166	n= 152	n= 118	n= 633	n= 392	n= 346	n= 268
IGA												
clear [0]	0 [0.0%]	9 [4.1%]	17 [8.9%]	12 [8.1%]	0 [0.0%]	6 [3.7%]	15 [9.9%]	8 [6.8%]	0 [0.0%]	15 [3.9%]	32 [9.2%]	20 [7.5%]
almost clear [1]	3 [0.9%]	62 [28.2%]	64 [33.3%]	58 [39.2%]	3 [1.1%]	35 [21.3%]	36 [23.7%]	29 [24.6%]	6 [1.0%]	97 [24.9%]	101 [29.2%]	87 [32.6%]
mild [2]	24 [7.0%]	94 [42.7%]	77 [40.1%]	52 [35.1%]	12 [4.3%]	66 [40.2%]	60 [39.5%]	62 [52.5%]	37 [5.9%]	163 [41.9%]	137 [39.6%]	115 [43.1%]
moderate [3]	154 [44.9%]	44 [20.0%]	32 [16.7%]	24 [16.2%]	111 [39.8%]	48 [29.3%]	36 [23.7%]	18 [15.3%]	266 [42.2%]	93 [23.9%]	68 [19.7%]	42 [15.7%]
severe [4]	129 [37.6%]	10 [4.5%]	2 [1.0%]	2 [1.4%]	122 [43.7%]	8 [4.9%]	5 [3.3%]	1 [0.8%]	255 [40.4%]	19 [4.9%]	8 [2.3%]	3 [1.1%]
very severe [5]	33 [9.6%]	1 [0.5%]	0 [0.0%]	0 [0.0%]	31 [11.1%]	1 [0.6%]	0 [0.0%]	0 [0.0%]	67 [10.6%]	2 [0.5%]	0 [0.0%]	0 [0.0%]
oSCORAD [mean]	44.0 ± 14.5	23.0 ± 12.4	19.5 ± 10.9	18.0 ± 9.2	47.0 ± 14.0	24.8 ± 12.7	20.8 ± 11.9	20.8 ± 10.1	45.4 ± 14.3	24.0 ± 12.6	20.1 ± 11.4	19.3 ± 9.7
EASI [mean]	19.2 ± 13.0	5.9 ± 6.9	3.8 ± 4.5	3.2 ± 4.0	21.2 ± 12.8	6.8 ± 7.7	4.5 ± 5.0	4.4 ± 4.6	20.1 ± 13.0	6.4 ± 7.5	4.1 ± 4.8	3.8 ± 4.3
EASI [head]	2.1 ± 1.6	0.8 ± 1.0	0.6 ± 0.7	0.5 ± 0.6	2.1 ± 1.6	0.9 ± 1.0	0.7 ± 0.9	0.7 ± 0.7	2.1 ± 1.6	0.8 ± 1.0	0.6 ± 0.8	0.6 ± 0.7
EASI [body]	5.4 ± 4.3	1.5 ± 2.4	1.1 ± 1.7	1.0 ± 1.6	6.1 ± 4.2	1.6 ± 2.4	1.2 ± 1.8	1.1 ± 1.6	5.7 ± 4.3	1.6 ± 2.4	1.1 ± 1.7	1.0 ± 1.6
EASI [arms]	4.4 ± 3.1	1.5 ± 1.7	0.9 ± 1.0	0.8 ± 1.0	4.9 ± 3.0	1.6 ± 1.9	1.1 ± 1.3	1.2 ± 1.4	4.7 ± 3.1	1.5 ± 1.8	1.0 ± 1.1	1.0 ± 1.2
EASI [legs]	7.3 ± 6.3	2.2 ± 3.2	1.3 ± 2.0	1.0 ± 1.7	8.1 ± 6.1	2.7 ± 3.8	1.5 ± 2.3	1.4 ± 2.1	7.7 ± 6.3	2.4 ± 3.6	1.4 ± 2.3	1.2 ± 1.9
PGA												
clear	0 [0.0%]	15 [6.8%]	12 [6.3%]	12 [8.2%]	0 [0.0%]	5 [3.1%]	8 [5.4%]	6 [5.3%]	0 [0.0%]	21 [5.5%]	20 [5.9%]	18 [6.9%]
almost clear	9 [2.6%]	72 [32.9%]	60 [31.6%]	51 [34.9%]	7 [2.5%]	41 [25.3%]	54 [36.2%]	33 [28.9%]	16 [2.6%]	113 [29.5%]	116 [34.0%]	84 [32.2%]
mild	53 [15.5%]	87 [39.7%]	89 [46.8%]	64 [43.8%]	28 [10.0%]	62 [38.3%]	54 [36.2%]	48 [42.1%]	81 [13.0%]	149 [38.9%]	143 [41.9%]	112 [42.9%]
moderate	110 [32.1%]	35 [16.0%]	27 [14.2%]	16 [11.0%]	73 [26.1%]	37 [22.8%]	22 [14.8%]	21 [18.4%]	183 [29.3%]	72 [18.8%]	49 [14.4%]	37 [14.2%]
severe	122 [35.6%]	10 [4.6%]	2 [1.1%]	2 [1.4%]	117 [41.8%]	14 [8.6%]	10 [6.7%]	6 [5.3%]	240 [38.5%]	25 [6.5%]	12 [3.5%]	9 [3.4%]
very severe	49 [14.3%]	0 [0.0%]	0 [0.0%]	1 [0.7%]	55 [19.6%]	3 [1.9%]	1 [0.7%]	0 [0.0%]	104 [16.7%]	3 [0.8%]	1 [0.3%]	1 [0.4%]
DLQI [mean]	10.9 ± 6.3	3.5 ± 3.8	3.1 ± 3.4	3.2 ± 3.7	17.2 ± 7.0	6.8 ± 7.0	5.9 ± 6.3	5.1 ± 4.9	13.8 ± 7.3	4.9 ± 5.6	4.3 ± 5.1	4.0 ± 4.4
POEM [mean]	17.7 ± 6.3	7.2 ± 5.6	6.7 ± 5.3	6.2 ± 5.2	21.4 ± 5.6	10.1 ± 6.9	8.5 ± 5.8	8.5 ± 5.5	19.4 ± 6.2	8.4 ± 6.3	7.5 ± 5.6	7.3 ± 5.5
Fatigue												
Fatigue [mean]	2.7 ± 0.8	2.5 ± 1.1	2.4 ± 1.1	2.2 ± 1.0	5.4 ± 0.8	4.0 ± 1.6	3.9 ± 1.5	3.8 ± 1.5	3.9 ± 1.6	3.2 ± 1.5	3.0 ± 1.5	2.9 ± 1.5
FSS ≤ 4	343 [100.0%]	198 [90.0%]	175 [92.1%]	138 [94.5%]	0 [0.0%]	86 [53.4%]	74 [50.0%]	66 [57.4%]	343 [55.0%]	286 [74.7%]	251 [73.8%]	205 [78.2%]
FSS > 4	0 [0.0%]	22 [10.0%]	15 [7.9%]	8 [5.5%]	281 [100.0%]	754 [46.5%]	74 [50.0%]	49 [42.6%]	281 [45.1%]	97 [25.3%]	89 [26.2%]	57 [21.8%]
CESD												
CESD [mean]	13.0 ± 8.3	9.2 ± 7.2	9.2 ± 7.4	8.1 ± 6.9	22.7 ± 10.1	16.7 ± 10.6	15.6 ± 10.5	14.4 ± 10.6	17.3 ± 10.3	12.3 ± 9.5	11.9 ± 9.4	10.9 ± 9.3
CESD < 16	239 [69.7%]	186 [84.5%]	162 [85.3%]	125 [87.4%]	0 [0.0%]	86 [53.4%]	74 [50.0%]	66 [57.4%]	316 [50.6%]	274 [71.7%]	247 [72.9%]	200 [77.2%]
CESD ≥ 16	104 [30.4%]	34 [15.4%]	28 [14.7%]	18 [12.6%]	281 [100.0%]	75 [36.5%]	74 [50.0%]	49 [42.6%]	309 [49.4%]	108 [28.3%]	96 [27.1%]	59 [22.8%]
pain [3 Tage]	4.0 ± 2.6	1.2 ± 1.7	1.3 ± 1.7	1.1 ± 1.5	5.2 ± 2.6	2.0 ± 2.3	2.1 ± 2.3	2.1 ± 2.2	4.6 ± 2.7	1.6 ± 2.0	1.6 ± 2.0	1.6 ± 1.9
itching [3 Tage]	6.3 ± 2.3	2.8 ± 2.1	2.6 ± 2.0	2.3 ± 1.9	7.3 ± 2.2	3.5 ± 2.4	3.4 ± 2.6	3.6 ± 2.3	6.8 ± 2.3	3.1 ± 2.3	2.9 ± 2.3	2.9 ± 2.2
insomnia [3 Tage]	4.7 ± 3.1	1.2 ± 1.9	1.1 ± 1.9	1.1 ± 1.8	6.8 ± 2.9	2.4 ± 2.9	2.2 ± 2.8	2.1 ± 2.7	5.7 ± 3.2	1.7 ± 2.4	1.6 ± 2.4	1.5 ± 2.3
EASI50		167 [76.3%]	164 [86.3%]	133 [89.9%]		130 [79.3%]	130 [87.2%]	103 [88.8%]		300 [77.3%]	296 [86.8%]	237 [89.4%]
EASI75		104 [47.5%]	130 [68.4%]	110 [74.3%]		78 [47.6%]	95 [63.8%]	76 [65.5%]		185 [47.7%]	226 [66.3%]	186 [70.2%]
EASI90		53 [24.2%]	65 [34.2%]	63 [42.6%]		33 [20.1%]	51 [34.2%]	41 [35.3%]		86 [22.2%]	116 [34.0%]	104 [39.2%]

Table SIII. Patient Needs Questionnaire (PNQ) and Patient Benefit Index (PBI) of AD patients treated with dupilumab within the TREATgermany registry at baseline (start of dupilumab therapy), after 3 months, 6 months, and 12 months, categorized by depressive symptom burden (CES-D < 16 vs ≥ 16). As PNQ data were recorded only at registry inclusion, the analysis was restricted to patients who initiated dupilumab at that visit. Percentages indicate the proportion of patients who rated a treatment goal as *important* or *very important* (PNQ) or reported that therapy helped *quite a lot* or *very much* to achieve the goal (PBI), each referring to patients for whom the respective goal was applicable.

	CESD < 16				CESD ≥ 16			
	expectation [PNQ]	realization [PBI] after...			expectation [PNQ]	realization [PBI] after...		
	start dupilumab	3 months	6 months	12 months	start dupilumab	3 months	6 months	12 months
	n = 268	n = 167	n = 167	n = 127	n = 271	n = 164	n = 155	n = 103
cohort size								
Needs related to physical impairments								
To be free of pain	212 [87.2%]	125 [86.2%]	144 [95.4%]	108 [93.1%]	226 [86.6%]	115 [76.2%]	121 [84.6%]	84 [90.3%]
To be free of itching	263 [98.9%]	133 [80.1%]	144 [87.3%]	108 [85.7%]	261 [97.4%]	112 [68.7%]	116 [75.3%]	78 [75.7%]
To no longer have a burning sensation on the skin	243 [93.8%]	131 [84.0%]	140 [89.7%]	104 [86.0%]	246 [93.5%]	118 [73.8%]	121 [80.1%]	83 [83.8%]
To be healed of all skin alterations	239 [90.2%]	112 [67.9%]	105 [64.8%]	85 [67.5%]	232 [86.6%]	88 [54.3%]	91 [58.7%]	59 [57.3%]
To be able to sleep better	213 [83.5%]	116 [80.0%]	116 [81.1%]	99 [89.2%]	243 [92.0%]	110 [71.4%]	109 [73.2%]	82 [83.7%]
Needs related to psychological impairments								
To feel less depressed	117 [54.2%]	74 [66.1%]	93 [73.8%]	73 [72.3%]	212 [80.6%]	82 [53.2%]	94 [62.7%]	66 [68.0%]
To gain in joy of living	158 [70.2%]	102 [79.7%]	113 [80.7%]	95 [89.6%]	227 [87.0%]	97 [62.2%]	106 [70.7%]	78 [77.2%]
To be able to lead a normal everyday life	203 [81.2%]	122 [87.1%]	131 [89.7%]	102 [88.7%]	250 [92.9%]	109 [68.6%]	115 [76.7%]	83 [84.7%]
To be more capable in daily life	180 [74.4%]	108 [78.8%]	118 [81.9%]	95 [84.1%]	225 [84.3%]	101 [63.9%]	103 [69.1%]	80 [81.6%]
To be able to engage in normal leisure activities	189 [79.4%]	97 [75.8%]	106 [77.4%]	84 [80.8%]	236 [90.4%]	93 [60.0%]	107 [73.3%]	76 [78.4%]
Needs related to social impairments								
To be less of a burden to relatives and friends	143 [65.9%]	87 [76.3%]	89 [76.7%]	69 [74.2%]	199 [77.4%]	99 [70.2%]	103 [75.7%]	82 [86.3%]
To be able to have a normal working life	157 [75.1%]	87 [82.1%]	93 [80.9%]	81 [82.7%]	201 [83.1%]	84 [66.1%]	88 [70.4%]	66 [79.5%]
To be able to have more contact with other people	109 [52.4%]	74 [71.2%]	84 [70.0%]	63 [73.3%]	185 [72.5%]	76 [56.7%]	85 [61.2%]	63 [66.3%]
To dare to show oneself more	164 [68.6%]	105 [77.8%]	112 [83.0%]	89 [80.9%]	215 [82.7%]	94 [61.0%]	96 [65.3%]	73 [75.3%]
To be less burdened in partnership	134 [63.5%]	78 [73.6%]	82 [74.5%]	60 [70.6%]	188 [85.5%]	72 [62.6%]	83 [70.3%]	64 [85.3%]
To be able to have a normal sex life	126 [62.7%]	66 [66.7%]	69 [68.3%]	54 [65.1%]	185 [82.6%]	71 [60.2%]	83 [71.6%]	55 [77.5%]
Needs related to impairments due to therapy								
To be less dependent on doctor and clinic visits	189 [72.4%]	108 [72.0%]	112 [73.7%]	84 [73.7%]	206 [76.9%]	101 [66.0%]	101 [71.6%]	74 [75.5%]
To have to spend less time with daily care	187 [71.6%]	113 [70.6%]	113 [71.1%]	90 [73.2%]	201 [74.7%]	100 [62.1%]	103 [66.9%]	76 [75.2%]
To have fewer out-of-pocket treatment costs	151 [60.9%]	79 [53.7%]	91 [61.9%]	70 [59.8%]	151 [57.9%]	79 [54.1%]	90 [65.7%]	66 [68.8%]
To experience fewer side effects	176 [71.8%]	83 [62.9%]	93 [65.5%]	78 [70.9%]	179 [71.3%]	72 [51.8%]	88 [65.2%]	61 [67.0%]
Needs related to confidence in healing								
To have no fear that the disease will progress	171 [70.1%]	105 [77.2%]	119 [82.6%]	85 [79.4%]	199 [78.0%]	95 [62.5%]	104 [70.3%]	72 [72.7%]
To find a clear diagnosis and therapy	227 [89.4%]	118 [78.1%]	134 [87.6%]	95 [81.2%]	228 [87.4%]	111 [72.1%]	117 [77.5%]	76 [76.8%]
To have confidence in the therapy	238 [91.9%]	146 [89.6%]	151 [93.2%]	113 [90.4%]	237 [89.8%]	121 [75.6%]	128 [83.7%]	82 [80.4%]
To experience faster improvement in the skin	245 [92.1%]	142 [86.6%]	155 [93.9%]	114 [90.5%]	242 [90.3%]	117 [71.8%]	124 [80.0%]	87 [84.5%]
To regain control over my illness	250 [95.4%]	143 [86.7%]	155 [93.9%]	112 [89.6%]	256 [95.9%]	123 [75.0%]	128 [83.7%]	86 [83.5%]

Table SIV. Patient Needs Questionnaire (PNQ) and Patient Benefit Index (PBI) of AD patients treated with dupilumab within the TREATgermany registry at baseline (start of dupilumab therapy), after 3 months, 6 months, and 12 months, categorized by fatigue level (FSS ≤ 4 vs > 4). As PNQ data were recorded only at registry inclusion, the analysis was restricted to patients who initiated dupilumab at that visit. Percentages indicate the proportion of patients who rated a treatment goal as *important* or *very important* (PNQ) or reported that therapy helped *quite a lot* or *very much* to achieve the goal (PBI), each referring to patients for whom the respective goal was applicable.

cohort size		FSS ≤ 4				FSS > 4			
		expectation [PNQ]	realization [PBQ] after...			expectation [PNQ]	realization [PBQ] after...		
		start dupilumab	3 months	6 months	12 months	start dupilumab	3 months	6 months	12 months
		n = 285	n = 185	n = 179	n = 123	n = 253	n = 146	n = 143	n = 107
Needs related to physical impairments									
	To be free of pain	225 [85.9%]	140 [85.4%]	148 [91.9%]	102 [93.6%]	212 [88.0%]	100 [75.8%]	117 [88.0%]	90 [90.0%]
	To be free of itching	276 [97.5%]	145 [78.8%]	154 [86.5%]	104 [85.2%]	247 [98.8%]	100 [69.0%]	106 [75.2%]	82 [76.6%]
To no longer have a burning sensation on the skin		256 [92.8%]	147 [85.0%]	151 [88.3%]	101 [87.1%]	232 [94.7%]	102 [71.3%]	110 [80.9%]	86 [82.7%]
	To be healed of all skin alterations	253 [89.7%]	119 [65.0%]	111 [62.7%]	78 [63.9%]	217 [86.8%]	81 [56.3%]	85 [60.7%]	66 [61.7%]
	To be able to sleep better	221 [81.3%]	124 [78.5%]	121 [76.6%]	97 [90.7%]	234 [95.1%]	102 [72.3%]	104 [77.6%]	84 [82.4%]
Needs related to psychological impairments									
	To feel less depressed	131 [55.0%]	86 [65.2%]	101 [71.6%]	73 [73.0%]	197 [82.1%]	70 [52.2%]	86 [63.7%]	66 [67.3%]
	To gain in joy of living	172 [69.4%]	110 [74.8%]	116 [75.8%]	93 [87.7%]	213 [89.5%]	89 [65.0%]	103 [75.2%]	80 [79.2%]
	To be able to lead a normal everyday life	221 [81.9%]	132 [82.5%]	138 [85.7%]	99 [89.2%]	231 [93.1%]	99 [71.2%]	108 [80.0%]	86 [84.3%]
	To be more capable in daily life	176 [67.7%]	116 [73.9%]	121 [77.1%]	92 [84.4%]	228 [91.9%]	93 [67.4%]	100 [73.5%]	83 [81.4%]
	To be able to engage in normal leisure activities	202 [79.2%]	105 [71.4%]	110 [72.8%]	82 [80.4%]	222 [91.4%]	85 [62.5%]	103 [78.0%]	78 [78.8%]
Needs related to social impairments									
	To be less of a burden to relatives and friends	149 [63.1%]	99 [76.2%]	97 [76.4%]	71 [75.5%]	193 [81.1%]	87 [69.6%]	95 [76.0%]	80 [85.1%]
	To be able to have a normal working life	166 [72.5%]	94 [75.8%]	94 [76.4%]	78 [82.1%]	191 [86.4%]	77 [70.6%]	87 [74.4%]	69 [80.2%]
To be able to have more contact with other people		123 [53.9%]	82 [67.8%]	92 [65.2%]	65 [72.2%]	170 [72.6%]	68 [58.1%]	77 [65.3%]	61 [67.0%]
	To dare to show oneself more	182 [70.8%]	117 [76.0%]	111 [72.1%]	87 [79.1%]	196 [81.3%]	82 [60.7%]	97 [75.8%]	75 [77.3%]
	To be less burdened in partnership	145 [64.7%]	79 [71.2%]	83 [72.2%]	66 [75.9%]	177 [85.5%]	71 [64.5%]	82 [72.6%]	58 [79.5%]
	To be able to have a normal sex life	141 [65.6%]	72 [65.5%]	71 [64.0%]	52 [68.4%]	170 [81.0%]	65 [60.7%]	81 [76.4%]	57 [73.1%]
Needs related to impairments due to therapy									
	To be less dependent on doctor and clinic visits	197 [71.1%]	123 [73.2%]	116 [73.4%]	84 [75.0%]	198 [78.9%]	86 [63.7%]	97 [71.9%]	74 [74.0%]
	To have to spend less time with daily care	194 [69.8%]	126 [70.4%]	116 [67.8%]	86 [72.3%]	193 [76.9%]	87 [61.3%]	100 [70.4%]	80 [76.2%]
	To have fewer out-of-pocket treatment costs	152 [57.1%]	90 [54.9%]	98 [63.2%]	71 [61.7%]	150 [61.7%]	68 [52.7%]	83 [64.3%]	65 [66.3%]
	To experience fewer side effects	171 [65.5%]	89 [58.9%]	97 [64.2%]	74 [68.5%]	184 [78.3%]	66 [55.0%]	84 [66.7%]	65 [69.9%]
Needs related to confidence in healing									
	To have no fear that the disease will progress	181 [69.3%]	120 [76.4%]	126 [78.8%]	81 [77.1%]	188 [79.3%]	80 [61.1%]	97 [73.5%]	76 [75.2%]
	To find a clear diagnosis and therapy	239 [88.2%]	129 [77.2%]	140 [83.8%]	92 [79.3%]	215 [88.5%]	100 [72.5%]	111 [81.0%]	79 [79.0%]
	To have confidence in the therapy	252 [91.6%]	158 [87.3%]	161 [92.0%]	110 [90.9%]	222 [89.9%]	109 [76.8%]	118 [84.3%]	85 [80.2%]
	To experience faster improvement in the skin	262 [92.9%]	154 [84.2%]	163 [92.1%]	109 [89.3%]	224 [89.2%]	105 [72.9%]	116 [81.1%]	92 [86.0%]
	To regain control over my illness	265 [94.6%]	159 [86.4%]	164 [92.7%]	107 [88.4%]	240 [96.8%]	107 [73.8%]	119 [84.4%]	91 [85.0%]

Table SV. Baseline characteristics of patients with and without complete 12-month follow-up data for CES-D and FSS in the TREATgermany registry.

	Available 12-months visit	No 12-months visit	Total
	N=268	N=365	N=633
Age [at start visit]	39.0 ± 14.2	40.0 ± 15.1	39.6 ± 14.7
Gender			
diverse	1 (0.4%)	0 (0.0%)	1 (0.2%)
male	155 (57.8%)	199 (54.5%)	354 (55.9%)
female	112 (41.8%)	166 (45.5%)	278 (43.9%)
Family status			
partnership [unmarried]	70 (26.5%)	107 (30.2%)	177 (28.6%)
married	92 (34.8%)	126 (35.6%)	218 (35.3%)
divorced	11 (4.2%)	11 (3.1%)	22 (3.6%)
widowed	3 (1.1%)	6 (1.7%)	9 (1.5%)
single	88 (33.3%)	104 (29.4%)	192 (31.1%)
School certificate			
without	1 (0.4%)	1 (0.3%)	2 (0.3%)
secondary school certificate	19 (7.1%)	40 (11.2%)	59 (9.4%)
secondary school diploma	89 (33.3%)	131 (36.6%)	220 (35.2%)
A-level	94 (35.2%)	99 (27.7%)	193 (30.9%)
university degree	64 (24.0%)	87 (24.3%)	151 (24.2%)
Employment			
no	56 (21.0%)	80 (22.3%)	136 (21.8%)
yes	211 (79.0%)	278 (77.7%)	489 (78.2%)
Smoking status			
smoker	65 (24.3%)	84 (23.5%)	149 (23.8%)
ex-smoker [< 10 years]	38 (14.2%)	49 (13.7%)	87 (13.9%)
ex-smoker [≥ 10 years]	32 (12.0%)	35 (9.8%)	67 (10.7%)
non smoker	132 (49.4%)	190 (53.1%)	322 (51.5%)
AD onset			
since infancy	162 (60.7%)	199 (55.7%)	361 (57.9%)
since before starting school	45 (16.9%)	59 (16.5%)	104 (16.7%)
since school/youth	30 (11.2%)	45 (12.6%)	75 (12.0%)
since adulthood	28 (10.5%)	53 (14.8%)	81 (13.0%)
unknown	2 (0.7%)	1 (0.3%)	3 (0.5%)
IGA			
clear [0]	3 (1.1%)	3 (0.8%)	6 (1.0%)
almost clear [1]	9 (3.4%)	28 (7.7%)	37 (5.9%)
mild [2]	108 (40.4%)	158 (43.4%)	266 (42.2%)
moderate [3]	114 (42.7%)	141 (38.7%)	255 (40.4%)
severe [4]	33 (12.4%)	34 (9.3%)	67 (10.6%)
oSCORAD [mean]	45.7 ± 14.9	45.2 ± 13.9	45.4 ± 14.3
EASI [mean]	20.4 ± 13.1	19.9 ± 13.0	20.1 ± 13.0
EASI [head]	2.2 ± 1.6	2.1 ± 1.5	2.1 ± 1.6
EASI [body]	5.8 ± 4.5	5.6 ± 4.1	5.7 ± 4.3
EASI [arms]	4.7 ± 3.0	4.6 ± 3.1	4.7 ± 3.1
EASI [legs]	7.7 ± 6.2	7.6 ± 6.3	7.7 ± 6.3
PGA			
clear	8 (3.0%)	8 (2.2%)	16 (2.6%)
almost clear	39 (14.7%)	42 (11.7%)	81 (13.0%)
mild	76 (28.6%)	107 (29.9%)	183 (29.3%)
moderate	103 (38.7%)	137 (38.3%)	240 (38.5%)
severe	40 (15.0%)	64 (17.9%)	104 (16.7%)
POEM [mean]	19.5 ± 6.1	19.2 ± 6.4	19.4 ± 6.2
Fatigue [mean]	3.8 ± 1.5	3.9 ± 1.6	3.9 ± 1.6
CESD [mean]	16.4 ± 9.8	18.0 ± 10.6	17.3 ± 10.3
pain	4.5 ± 2.5	4.6 ± 2.8	4.6 ± 2.7
itching	6.6 ± 2.2	6.9 ± 2.3	6.8 ± 2.3
insomnia	5.8 ± 3.0	5.6 ± 3.3	5.7 ± 3.2

Table SVI. Availability of 1-year follow-up data among AD patients treated with dupilumab within the TREATgermany registry

Status at 1 year	n	% of 633
Available 1-year visit	268	42.3%
Administrative censoring (initiated < 1 year before data cut-off, December 2023)	108	17.1%
Still on dupilumab at 1 year, visit outside the predefined 1-year window	146	23.1%
Lost to follow-up	73	11.5%
Confirmed dupilumab discontinuation within the first year	38	6.0%
Total	633	100.0%